Central microperimetry and radial OCT in geographic atrophy
Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 55 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT07556406 on ClinicalTrials.gov |
What this trial studies
This prospective pilot at the University of California, San Francisco uses central microperimetry and radial OCT imaging to track structural and functional changes in patients with geographic atrophy (GA) or those at risk. Participants undergo repeated OCT and microperimetry to measure GA area and retinal sensitivity, with emphasis on progression toward the foveal center. The study enrolls adults aged 55 and older with non-central GA or intermediate AMD and excludes eyes with existing central foveal involvement or very large GA. Outcomes will compare whether combining radial OCT with central microperimetry gives finer measurement of central progression than standard approaches.
Who should consider this trial
Good fit: Adults 55 and older with intermediate AMD or with non-central geographic atrophy (GA not involving the foveal center) and at least 1% GA in the central 1 mm zone are ideal candidates.
Not a fit: Patients whose GA already involves the foveal center, who have very large baseline GA (>17.5 mm²), retinal atrophy from other causes, or who cannot undergo or complete imaging visits (including those unable to consent or with exclusionary conditions) are unlikely to benefit.
Why it matters
Potential benefit: If successful, these imaging approaches could detect central progression earlier or more precisely, helping clinicians monitor vision risk and time interventions better.
How similar studies have performed: Prior work has shown OCT and microperimetry can track structural and functional GA changes, but combining central microperimetry with radial OCT specifically to measure progression toward the fovea is a relatively novel pilot approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects must be 55+ years of age Subjects in the "Intermediate AMD Observation Arm" must have intermediate age-related macular degeneration in one eye Subjects in the "GA Observation Arm", "GA Continuing Treatment Arm", and "GA Treatment Arm" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone. Exclusion Criteria: * Subjects with central involvement of GA. Central involvement is defined as geographic atrophy involving the foveal center point. Subjects with a baseline size of GA \> 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas). Subjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g/dL) on 5 or more days in the past month. Evidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to): 1. Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy 2. Branch or central retinal vein or artery occlusion 3. Macular hole 4. Pathologic myopia 5. Uveitis 6. Pseudovitelliform maculopathy 7. Intraoperative surgery within the last 90 days prior to study eye enrollment
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Jay Stewart, MD — University of California, San Francisco
- Study coordinator: Jay M Stewart, MD
- Email: eyestudy@ucsf.edu
- Phone: (628) 206-3123
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.